BACKGROUND: Although neoadjuvant chemotherapy (NCT) is standard therapy for locally advanced breast cancer, it remains controversial for early-stage disease due to concerns that disease progression may make breast-conservation therapy (BCT), or even operability, impossible. The goal of this study was to determine the impact of disease progression during NCT on surgical management. METHODS: We reviewed clinicopathological data on patients who received NCT for stage I-III breast cancer from 1994 to 2007. Chemotherapy regimens were anthracycline-and/or taxane-based as determined by the treating medical oncologist. RESULTS: Of 1,928 patients who received NCT, 1,762 (91%) had a partial or complete response, 107 (6%) had stable disease (SD), and 59 (3%) progressed (PD) while receiving at least one regimen. Of the patients with progressive disease, 40 (68%) patients underwent mastectomy, 12 (20%) underwent BCT, and 7 (12%) did not undergo surgery. In patients who underwent mastectomy, only three (8%) were BCT candidates before progression. Overall, disease progression changed the operative plan in 11 (0.5%) patients: 3 developed distant metastasis, 2 developed clinical lymphadenopathy, 3 required mastectomy instead of BCT, 2 became inoperable, and 1 required flap closure. CONCLUSIONS: Disease progression while receiving NCT is infrequent (3%), but early identification may allow for change to other, potentially beneficial, therapeutic interventions. Patients with breast cancer who receive NCT should be evaluated frequently for response to therapy. Overall, progression during NCT changes the surgical management in a small proportion of patients.
BACKGROUND: Although neoadjuvant chemotherapy (NCT) is standard therapy for locally advanced breast cancer, it remains controversial for early-stage disease due to concerns that disease progression may make breast-conservation therapy (BCT), or even operability, impossible. The goal of this study was to determine the impact of disease progression during NCT on surgical management. METHODS: We reviewed clinicopathological data on patients who received NCT for stage I-III breast cancer from 1994 to 2007. Chemotherapy regimens were anthracycline-and/or taxane-based as determined by the treating medical oncologist. RESULTS: Of 1,928 patients who received NCT, 1,762 (91%) had a partial or complete response, 107 (6%) had stable disease (SD), and 59 (3%) progressed (PD) while receiving at least one regimen. Of the patients with progressive disease, 40 (68%) patients underwent mastectomy, 12 (20%) underwent BCT, and 7 (12%) did not undergo surgery. In patients who underwent mastectomy, only three (8%) were BCT candidates before progression. Overall, disease progression changed the operative plan in 11 (0.5%) patients: 3 developed distant metastasis, 2 developed clinical lymphadenopathy, 3 required mastectomy instead of BCT, 2 became inoperable, and 1 required flap closure. CONCLUSIONS: Disease progression while receiving NCT is infrequent (3%), but early identification may allow for change to other, potentially beneficial, therapeutic interventions. Patients with breast cancer who receive NCT should be evaluated frequently for response to therapy. Overall, progression during NCT changes the surgical management in a small proportion of patients.
Authors: Judy C Boughey; Jamie Wagner; Betsy J Garrett; Lori Harker; Lavinia P Middleton; Gildy V Babiera; Funda Meric-Bernstam; Anthony Lucci; Kelly K Hunt; Isabelle Bedrosian Journal: Ann Surg Oncol Date: 2009-03-12 Impact factor: 5.344
Authors: Abigail S Caudle; Ana M Gonzalez-Angulo; Kelly K Hunt; Ping Liu; Lajos Pusztai; W Fraser Symmans; Henry M Kuerer; Elizabeth A Mittendorf; Gabriel N Hortobagyi; Funda Meric-Bernstam Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Judy C Boughey; Florentia Peintinger; Funda Meric-Bernstam; Allison C Perry; Kelly K Hunt; Gildy V Babiera; S E Singletary; Isabelle Bedrosian; Anthony Lucci; Aman U Buzdar; Lajos Pusztai; Henry M Kuerer Journal: Ann Surg Date: 2006-09 Impact factor: 12.969
Authors: Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-04-10 Impact factor: 44.544
Authors: B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Johanna G H van Nes; Hein Putter; Jean-Pierre Julien; Michelle Tubiana-Hulin; Marc van de Vijver; Jan Bogaerts; Monika de Vos; Cornelis J H van de Velde Journal: Breast Cancer Res Treat Date: 2008-05-18 Impact factor: 4.872
Authors: Carla J Christy; David Thorsteinsson; Baiba J Grube; Dalliah Black; Maysa Abu-Khalaf; Gina G Chung; Michael P DiGiovanna; Kenneth Miller; Susan A Higgins; Joanne Weidhaas; Lyndsay Harris; Fattaneh A Tavassoli; Donald R Lannin Journal: Ann Surg Oncol Date: 2009-01-09 Impact factor: 5.344
Authors: I F Faneyte; J G Schrama; J L Peterse; P L Remijnse; S Rodenhuis; M J van de Vijver Journal: Br J Cancer Date: 2003-02-10 Impact factor: 7.640
Authors: Aman U Buzdar; Vera J Suman; Funda Meric-Bernstam; Ann Marilyn Leitch; Matthew J Ellis; Judy C Boughey; Gary W Unzeitig; Melanie E Royce; Kelly K Hunt Journal: JAMA Oncol Date: 2019-01-01 Impact factor: 31.777
Authors: F Giugliano; J Uliano; V A A Zia; D Trapani; A Marra; G Viale; E Ferraro; A Esposito; C Criscitiello; P D'amico; G Curigliano Journal: Breast Cancer Res Treat Date: 2021-05-27 Impact factor: 4.872
Authors: Rob van Bommel; Adri C Voogd; Marieke W Louwman; Luc J Strobbe; Dick Venderink; Lucien E M Duijm Journal: Eur Radiol Date: 2016-05-14 Impact factor: 5.315
Authors: Kandace P McGuire; E Shelley Hwang; Alan Cantor; Mehra Golshan; Funda Meric-Bernstam; Janet K Horton; Rita Nanda; Keith D Amos; Andres Forero; Cliff A Hudis; Ingrid Meszoely; Jennifer F De Los Santos Journal: Ann Surg Oncol Date: 2014-07-25 Impact factor: 5.344
Authors: Tomás Pascual; Mafalda Oliveira; Patricia Villagrasa; Vanesa Ortega; Laia Paré; Begoña Bermejo; Serafín Morales; Kepa Amillano; Rafael López; Patricia Galván; Jordi Canes; Fernando Salvador; Paolo Nuciforo; Isabel T Rubio; Antonio Llombart-Cussac; Serena Di Cosimo; José Baselga; Nadia Harbeck; Aleix Prat; Javier Cortés Journal: NPJ Breast Cancer Date: 2021-11-25